Profile data is unavailable for this security.
About the company
Shanghai OPM Biosciences Co Ltd is a China-based company mainly engaged in cell culture products and services. The Company's main business involves two application areas: cell culture medium series products and biopharmaceutical contract development and production services. The Company's cell culture medium series products are widely used in the production of biological products such as protein/antibody production, vaccine production, cell therapy/gene therapy, and others. The Company's antibody drug development contract development and manufacturing organization (CDMO) service platform is committed to providing domestic and foreign customers with full-process services from antibody engineering humanization screening, cell line construction, process development to pilot production and clinical I&II phase sample production.
- Revenue in CNY (TTM)265.48m
- Net income in CNY40.29m
- Incorporated2013
- Employees285.00
- LocationShanghai OPM Biosciences Co LtdBlock 28Lane 908, Ziping Road, Pudong New AeraSHANGHAI 201321ChinaCHN
- Phone+86 2 120780178
- Fax+86 2 168101069
- Websitehttp://www.opmbiosciences.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shanghai OPM Biosciences Co Ltd | 265.48m | 40.29m | 3.74bn | 285.00 | 92.97 | 1.74 | -- | 14.09 | 0.3507 | 0.3507 | 2.31 | 18.70 | 0.1165 | 2.10 | 2.75 | 931,523.80 | 1.73 | 4.34 | 1.78 | 4.65 | 57.66 | 58.31 | 14.86 | 23.40 | 20.08 | -- | 0.0328 | 45.38 | -17.41 | 48.34 | -48.72 | -- | 6.09 | -- |
Tibet Weixinkang Pharmaceutical Co Ltd | 1.21bn | 243.48m | 3.81bn | 701.00 | 15.64 | 2.71 | -- | 3.16 | 0.5595 | 0.5595 | 2.77 | 3.22 | 0.6649 | 17.00 | 5.18 | 1,721,074.00 | 13.42 | 8.20 | 17.74 | 11.13 | 51.43 | 50.20 | 20.18 | 11.53 | 2.75 | -- | 0.0073 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
Jiangsu Aidea Pharmaceutical Co Ltd | 353.69m | -111.90m | 3.90bn | 476.00 | -- | 3.60 | -- | 11.04 | -0.2622 | -0.2622 | 0.8398 | 2.58 | 0.204 | 1.01 | 1.68 | 743,045.90 | -6.45 | -2.40 | -9.06 | -2.85 | 45.04 | 39.00 | -31.64 | -10.15 | 1.13 | -- | 0.281 | -- | 68.44 | 8.24 | 38.75 | -- | -4.47 | -- |
Beijing Konruns Pharmaceutical Co Ltd | 874.20m | 136.76m | 3.91bn | 447.00 | 28.24 | 1.24 | -- | 4.47 | 0.8643 | 0.8643 | 5.51 | 19.63 | 0.2293 | 1.82 | 3.01 | 1,955,707.00 | 4.50 | 5.43 | 5.31 | 6.24 | 88.30 | 89.93 | 19.62 | 20.76 | 2.93 | -- | 0.0435 | 21.53 | 6.15 | -2.08 | 48.24 | -10.63 | 43.05 | -9.71 |
Zhejiang Starry Pharmaceutical Co Ltd | 2.44bn | 31.85m | 3.96bn | 1.85k | 103.59 | 1.47 | -- | 1.62 | 0.0873 | 0.0873 | 6.75 | 6.16 | 0.4204 | 1.89 | 5.34 | 1,323,881.00 | 0.5588 | 3.30 | 1.13 | 5.97 | 22.38 | 32.35 | 1.33 | 8.21 | 0.6491 | 1.34 | 0.5201 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
Holder | Shares | % Held |
---|---|---|
Shenzhen Fortune Caizhi Venture Capital Management Co., Ltd.as of 09 May 2024 | 5.74m | 7.60% |
China Merchants Fund Management Co., Ltd.as of 31 Dec 2023 | 2.75m | 3.64% |
Huashang Fund Management Co., Ltd.as of 31 Dec 2023 | 1.64m | 2.18% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 1.39m | 1.84% |
Golden Trust Sinopac Fund Management Co., Ltd.as of 31 Dec 2023 | 1.34m | 1.78% |
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 1.07m | 1.42% |
HSBC Jintrust Fund Management Co. Ltd.as of 31 Dec 2023 | 1.07m | 1.41% |
Baoying Fund Management Co., Ltd.as of 31 Dec 2023 | 1.06m | 1.40% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 655.52k | 0.87% |
Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 610.58k | 0.81% |